SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-23-015754
Filing Date
2023-04-28
Accepted
2023-04-28 16:01:39
Documents
11
Period of Report
2023-06-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A eypt_def_14a_04-28-2023.htm DEF 14A 1670096
2 GRAPHIC img140859135_0.jpg GRAPHIC 31402
3 GRAPHIC img140859135_1.jpg GRAPHIC 17314
4 GRAPHIC img140859135_2.jpg GRAPHIC 2513
5 GRAPHIC img140859135_3.jpg GRAPHIC 31402
6 GRAPHIC img140859135_4.jpg GRAPHIC 17608
7 GRAPHIC img140859135_5.jpg GRAPHIC 31402
8 GRAPHIC img140859135_6.jpg GRAPHIC 71226
9 GRAPHIC img140859135_7.jpg GRAPHIC 269700
10 GRAPHIC img140859135_8.jpg GRAPHIC 1439165
11 GRAPHIC img140859135_9.jpg GRAPHIC 961578
  Complete submission text file 0000950170-23-015754.txt   5625152
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-51122 | Film No.: 23865723
SIC: 3826 Laboratory Analytical Instruments
Industrial Applications and Services